Document Detail


The economics of priority review vouchers.
MedLine Citation:
PMID:  20732445     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
Priority review vouchers (PRVs) were introduced in 2007 by the US Congress as an incentive mechanism to spur pharmaceutical firms' R&D efforts for neglected diseases (NDs). A voucher, which a firm can obtain upon approval of a new treatment for NDs, entitles the holder to prioritize the FDA review for any drug. The proposal generated much controversy regarding its ability to effectively stimulate R&D for NDs. Here, after reviewing the main issues of the debate, i use a stylized economic model to discuss the strength of PRVs as an economic incentive to invest in research. My findings suggest that R&D investments might be higher when the developer could prioritize a valuable compound.
Authors:
Nicola Dimitri
Related Documents :
123015 - Chymopapain chemonucleolysis in lumbar disk disease.
11347725 - Temporal patterns of nsaid spontaneous adverse event reports: the weber effect revisited.
23634425 - Organic mania in dengue.
23824465 - Are the precapillary sphincters and metarterioles universal components of the microcirc...
15040625 - Safety concerns regarding ephedrine-type alkaloid-containing dietary supplements.
3560075 - Lithopedion. a case report.
Publication Detail:
Type:  Journal Article     Date:  2010-08-21
Journal Detail:
Title:  Drug discovery today     Volume:  15     ISSN:  1878-5832     ISO Abbreviation:  Drug Discov. Today     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-11-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9604391     Medline TA:  Drug Discov Today     Country:  England    
Other Details:
Languages:  eng     Pagination:  887-91     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Ltd. All rights reserved.
Affiliation:
Faculty of Economics, University of Siena, 53100, Italy. dimitri@unisi.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Activin A induces SLC5A8 expression through the Smad3 signaling pathway in human colon cancer RKO ce...
Next Document:  The MPTP marmoset model of parkinsonism: a multi-purpose non-human primate model for neurodegenerati...